

- (3) U.S. Patent No. 5,616,566, issued April 01, 1997, entitled "Method of Inhibiting HIV Replication with 2', 3'-Dideoxyadenosine" (PHS Reference No. E-081-87/6)
- (4) U.S. Patent Application No. 08/246,916, filed May 20, 1994, entitled "Antiviral Compositions and Methods" (PHS Reference No. E-081-87/7)
- (5) U.S. Patent No. 5,026,687, issued June 25, 1991, entitled "Treatment of Human Retroviral Infections with 2', 3'-Dideoxyinosine" (PHS Reference No. E-051-90/0)
- (6) U.S. Patent No. 5,376,642, issued December 27, 1994, entitled "Treatment of Human Retroviral Infections with 2', 3'-Dideoxyinosine" (PHS Reference No. E-051-90/2)

**ADDRESSES:** Licensing information may be obtained by contacting Sally Hu, Ph.D., M.B.A., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; Telephone: 301/496-7056 ext. 265; Fax: 301/402-0220; E-mail: hus@od.nih.gov.

**SUPPLEMENTARY INFORMATION:** Human Immunodeficiency Virus (HIV) and other retroviruses need three viral enzymes for replication: reverse transcriptase (RT), protease and integrase. The current focus for treatment of acquired immune deficiency syndrome (AIDS) is the development of antiviral drugs that target the infection and replication of HIV. The patents and patent applications describe group novel compounds discovered by Dr. Hiroaki Mitsuya, Dr. Robert Yarchoan and Dr. Samuel Broder at the National Cancer Institute. It has been shown that the drugs 2', 3'-dideoxyinosine (ddI), 2', 3'-dideoxyadenosine (ddA), and 2', 3'-dideoxyguanosine (ddG), and their triphosphate derivatives are useful for treatment of retroviral infections, particularly HIV-infection and AIDS. ddI, ddA, and ddG are metabolized *in vivo* to active triphosphate derivatives that inhibit HIV and retroviral reverse transcriptase, an enzyme required for retroviral replication. Liposomal encapsulated dideoxynucleosides, salts and esters are also claimed since triphosphates ordinarily do not penetrate cell membranes and the triphosphate derivatives of this invention are delivered by liposomes, small particles that serve as intracellular transport systems. ddI (didanosine) is licensed for human use in the U.S. and around the world as a treatment for HIV infections.

Dated: November 6, 2001.

**Jack Spiegel,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer.*

[FR Doc. 01-28706 Filed 11-15-01; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Initial Review Group, Subcommittee D—Clinical Studies.

*Date:* December 4-5, 2001.

*Time:* 7 pm to 4 pm.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

*Contact Person:* William D. Merritt, PhD, Scientific Review Administrator, Grants Review Branch, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8129, MSC 8328, Bethesda, MD 20892-8328, 301-496-9767.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: November 6, 2001.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 01-28694 Filed 11-15-01; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institutes of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Neurological Disorders and Stroke Special Emphasis Panel.

*Date:* November 27, 2001.

*Time:* 2 pm to 5 pm.

*Agenda:* To review and evaluate grant applications.

*Place:* 6001 Executive Blvd., Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Raul A. Saavedra, PhD., Scientific Review Administrator Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892-9529, 301-496-9223.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: November 7, 2001.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 01-28696 Filed 11-15-01; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as